VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 03/04/21
VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic DermatitisGlobeNewsWire • 03/01/21
Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And MoreBenzinga • 02/06/21
VYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate UpdateGlobeNewsWire • 01/29/21
VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 01/26/21
VYNE Stock: 13 Things to Know About Vyne Therapeutics as Shares Rocket HigherInvestorPlace • 01/25/21
VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) CompanyGlobeNewsWire • 01/21/21
VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in AcneGlobeNewsWire • 12/17/20
VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare ConferenceGlobeNewsWire • 11/25/20
VYNE Therapeutics (VYNE) CEO David Domzalski on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/10/20
Vyne Therapeutics: Strong Execution And Potential Upside From Strategic OptionsSeeking Alpha • 10/12/20
VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express ScriptsPRNewsWire • 10/07/20
VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1stPRNewsWire • 10/01/20
VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% is Available in Pharmacies Nationwide Today, October 1stGlobeNewsWire • 10/01/20
VYNE Therapeutics Announces the Appointment of Patrick G. LePore to its Board of DirectorsGlobeNewsWire • 09/14/20